SEVERITY, NOT PRESENCE, OF DIASTOLIC DYSFUNCTION DRIVES PERIOPERATIVE CARDIOVASCULAR RISK BEFORE NON-CARDIAC SURGERY: A PROSPECTIVE COHORT STUDY PROPOSING A SEVERITY-FIRST TRIAGE FRAMEWORK.

Abstract:

Background: Diastolic dysfunction (DD) with preserved ejection fraction is prevalent before non-cardiac surgery, yet its prognostic weight remains contested. Guidelines flag DD without an actionable threshold. We hypothesized that DD severity, indexed by elevated left ventricular filling pressures (LVFP), drives perioperative risk.

Methods: This prospective single-center cohort enrolled 102 adults scheduled for elective non-cardiac surgery (March 2025 to February 2026). All underwent preoperative transthoracic echocardiography per 2016 ASE/EACVI criteria. Isolated DD was preserved left ventricular ejection fraction (LVEF) ≥ 50% with abnormal diastolic function. The primary endpoint was in-hospital major adverse cardiovascular events (MACE), comparing isolated DD (n = 44) and normal controls (n = 36). Performance used logistic regression with bootstrap-corrected area under the curve (AUC).

Results: Of 80 LVEF-preserved patients, 55.0% had isolated DD, with heavier comorbidity (diabetes 59.1% vs. 16.7%, P < 0.001) and 7-fold higher median NT-proBNP (733 vs. 98 pg/ml, P < 0.001). MACE rates were similar (22.7% vs. 16.7%; odds ratio [OR] 1.47, 95% confidence interval [CI] 0.48 to 4.53). Binary DD added negligible discrimination over Lee plus NT-proBNP (ΔAUC +0.002); severe DD trended stronger (OR 3.22, 95% CI 0.79 to 13.19), lifting AUC from 0.70 to 0.77. Isolated DD prompted a 5-fold rise in preoperative optimization (50.0% vs. 11.1%, P < 0.001).

Conclusions: DD should be treated not as a binary alarm but as a graded signal whose severity, indexed by LVFP, drives prognosis. We propose a Severity-First Diastolic Triage framework integrating Lee score, NT-proBNP, and LVFP to rationalize preoperative echocardiography.

Key words:-

Diastolic heart failure; Echocardiography; Heart failure with preserved ejection fraction; Natriuretic peptide, brain; Noncardiac surgery; Perioperative care; Preoperative care; Risk assessment; Ventricular dysfunction, left.

Introduction:-

Heart failure with preserved ejection fraction (HFpEF) now accounts for approximately half of all incident heart failure cases worldwide, and its prevalence is rising with population aging and the global epidemic of cardiometabolic disease [1,2]. Left ventricular diastolic dysfunction (DD)—the morphological substrate of HFpEF—follows a pathophysiological continuum from isolated impaired relaxation to elevated filling pressures and overt clinical decompensation [3,4]. In community cohorts, DD affects 30% to 50% of adults over 60 years of age [5,6] and rises to 55% or more among patients presenting for elective non-cardiac surgery [7].

In the perioperative arena, this matters acutely. General anesthesia, surgical stress, and large fluid shifts impose hemodynamic loads that a stiff, non-compliant ventricle tolerates poorly: subendocardial ischemia, atrial fibrillation, pulmonary congestion, and demand–supply ischemic injury are all overrepresented in patients with abnormal diastolic function [8–10]. The recently published 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM perioperative cardiovascular guideline [11] and the 2022 ESC/ESAIC guideline [12] both flag DD as a relevant prognostic marker, but neither specifies a clinical threshold for action, and routine preoperative transthoracic echocardiography (TTE) is explicitly not recommended [11,12].

Three problems have so far kept the field paralyzed. First, DD is rarely truly isolated in the published evidence base: most retrospective series mix patients with concomitant systolic dysfunction or hypertrophy, blurring its independent contribution [13,14]. Second, the very definition of DD has shifted across the 2009 and 2016 ASE/EACVI iterations, with a decisive move from the E/A ratio toward integrated assessment of left ventricular filling pressures (LVFP) [15]. Third, and most importantly, the prognostic gain of DD must now be tested incrementally against well-validated tools—the Revised Cardiac Risk Index (Lee score), NT-proBNP [16,17], and the Duke Activity Status Index [18]—rather than in isolation. The SOLOMON study (2023) demonstrated that even global longitudinal strain offers only modest incremental discrimination over established scores [19], reinforcing the need for parsimony when adding echocardiographic parameters to perioperative risk models.

A consequence of this paralysis is clinical: the simple mention of “diastolic dysfunction” on a preoperative TTE report continues to trigger disproportionate care escalations—cardiology consultation, surgery deferral, intensive care unit (ICU) pre-admission—in patients in whom the true incremental risk is small. Conversely,

UNDER PEER REVIEW IN IJAR

severe DD with elevated LVFP, which does carry meaningful risk, is sometimes lost in the noise. The field needs a disciplined, severity-graded approach that the anesthesiologist can apply at the bedside.

Against this background, we conducted a prospective single-center cohort study with three prespecified objectives: (1) to characterize the prevalence and clinical phenotype of isolated DD with preserved LVEF in consecutive non-cardiac surgical patients; (2) to quantify its association with cardiovascular comorbidities, NT-proBNP elevation, and preoperative therapeutic decision-making; and (3) to test, against established predictors (Lee score, NT-proBNP, surgical risk), the hypothesis that DD severity—captured by elevated LVFP—rather than its binary presence, drives perioperative MACE risk. Building on our findings, we propose a Severity-First Diastolic Triage (SFDT) framework intended to rationalize the preoperative echocardiographic decision pathway, in line with the 2024 AHA/ACC [11] and 2023 ESC focused update on heart failure [20].

Materials and Methods:-

Study design and setting

This was a prospective single-center observational cohort study conducted at Oued Eddahab Military hospital between 17 March 2025 and 1 February 2026. The protocol was approved by "Comité d'Ethique pour la Recherche Biomédicale Université Mohammed V CERB – Rabat" with approval number 31/25 by the local Institutional Review Board and complied with the Declaration of Helsinki (revised 2013) and the STROBE statement for observational studies [21]. Written informed consent was obtained from every participant. The study was not interventional; all clinical decisions remained the responsibility of the attending teams.

Participants

Consecutive adults (≥ 18 years of age) admitted for elective non-cardiac surgery and seen at the standardized preoperative anesthesia consultation were eligible. Exclusion criteria were: emergency surgery; cardiac or thoracic surgery; chronic renal replacement therapy; and inability to obtain interpretable echocardiographic windows. No patient was excluded on the basis of age, comorbidity burden, or surgical risk class. The sex of all participants was recorded. The study cohort included both male and female adults; no a priori sex-based exclusion was applied.

Echocardiographic assessment

All TTE examinations were performed by a single experienced cardiologist blinded to clinical outcomes, using a standard echocardiography system equipped with a 2.5–3.5 MHz transducer. Image acquisition and analysis followed the 2016 ASE/EACVI recommendations [15].

LVEF was calculated by the modified biplane Simpson method; preserved LVEF was defined as ≥ 50%. Diastolic function was classified per the 2016 ASE/EACVI algorithm integrating septal and lateral mitral annular tissue Doppler velocities (e′), average E/e′ ratio, indexed left atrial volume, and peak tricuspid regurgitation velocity. Categories were: (1) normal; (2) isolated impaired relaxation (mild DD); (3) abnormal compliance; and (4) combined relaxation and compliance abnormalities (advanced DD). LVFP was classified as normal or elevated by the same algorithm; elevated LVFP defined severe DD.

Four echocardiographic phenotypes were prespecified by combining LVEF and diastolic function: (1) Normal—preserved LVEF + normal diastolic function; (2) Isolated DD—preserved LVEF + abnormal diastolic function; (3) Combined SD + DD—reduced LVEF + abnormal diastolic function; and (4) Isolated SD—reduced LVEF + normal diastolic function. The primary analytic comparison contrasted Isolated DD with Normal (preserved-LVEF cohort, n = 80).

Clinical and laboratory variables

Demographics, cardiovascular risk factors (diabetes, hypertension, dyslipidemia, obesity, smoking), cardiovascular history, current medications, New York Heart Association (NYHA) dyspnea class, full six-item Lee/Revised Cardiac Risk Index (RCRI) [22], surgical risk stratum per 2022 ESC criteria [12], and preoperative NT-proBNP (within 30 days of surgery, by a single standardized electrochemiluminescence assay) were recorded prospectively on a structured case-report form. The 300 pg/ml NT-proBNP threshold from the 2022 ESC/ESAIC guideline [12] was used as the principal cut-off, with sensitivity analyses at the 125 pg/ml threshold endorsed by recent VISION substudies [16].

Outcomes

The primary outcome was a composite of in-hospital major adverse cardiovascular events (MACE), prespecified as: all-cause death; non-fatal myocardial infarction (per the Fourth Universal Definition [23]); cardiogenic

UNDER PEER REVIEW IN IJAR

shock; acute respiratory failure requiring ventilatory support; symptomatic arrhythmia requiring intervention; or unplanned admission to the intensive or intermediate care unit. Secondary outcomes were: preoperative therapeutic adjustments (initiation/modification of beta-blockers, diuretics, statins, antithrombotic agents, or blood-pressure optimization); preoperative admission for medical optimization; intraoperative red-cell transfusion; and length of hospital stay. Outcomes were adjudicated by two reviewers blinded to echocardiographic phenotype; disagreements were resolved by consensus.

Sample size and statistical analysis

With 102 consecutively enrolled patients and an expected MACE incidence of approximately 20% in the LVEF-preserved cohort, the study had 80% power at two-sided $\alpha = 0.05$ to detect an odds ratio of ≥ 3.5 for isolated DD as a binary predictor—an effect size in keeping with prior estimates [14,24]. We acknowledge that the study was underpowered for detecting smaller effects, and we therefore framed isolated-DD analyses as exploratory.

Categorical variables are reported as n (%); continuous variables as mean ± standard deviation (SD) or median (Q1, Q3) depending on distribution, assessed by the Shapiro–Wilk test. Two-group comparisons used the chi-squared test or Fisher's exact test for categorical variables, and the Mann–Whitney U test for continuous variables. Univariable and multivariable logistic regression identified MACE predictors; variable selection for the multivariable model was guided by clinical prespecification rather than data-driven stepwise procedures, to limit overfitting given the limited number of events per variable. Discriminative performance was assessed by the area under the receiver-operating-characteristic curve (AUC) with bootstrap 95% CI (2,000 replicates). The incremental value of DD added to a Lee + NT-proBNP base model was tested by paired-bootstrap AUC comparison [25]. Internal validation used 1,000 bootstrap replicates to estimate optimism. Sensitivity, specificity, and predictive values were calculated for isolated DD and elevated LVFP as standalone tests. All analyses were performed with Python version 3.12 (SciPy version 1.17, scikit-learn version 1.8); two-sided P values < 0.05 were considered significant. Reporting of the prediction-model component followed the TRIPOD statement [26]. Missing data were minimal ($< 3\%$ per variable); complete-case analysis was used and no imputation was performed.

Declaration of use of generative artificial intelligence

A large language model was used solely for language refinement and structural revision of the manuscript draft. It was not used for study design, data collection, statistical analysis, or generation of figures or references. The authors verified and take full responsibility for all content.

Results:-

Cohort characteristics and echocardiographic phenotypes

Of 102 analyzable patients (mean age 68.8 ± 10.3 years; 43.1% male), the echocardiographic phenotype distribution was: Normal 36 (35.3%), Isolated DD 44 (43.1%), SD + DD 20 (19.6%), and Isolated SD 2 (2.0%) (Fig. 1A). Among the 80 LVEF-preserved patients (78.4%), 44 (55.0%) met criteria for isolated DD—numerically dominating the LVEF-preserved subgroup.

NT-proBNP differed strikingly across phenotypes (Fig. 1B): median 98 (Q1–Q3: 59 to 239) pg/ml in Normal patients, 733 (173 to 981) pg/ml in Isolated DD, and 950 (414 to 3,216) pg/ml in SD + DD ($P < 0.001$ for between-group comparison). Isolated DD patients therefore had a 7-fold higher median NT-proBNP than phenotypically normal patients despite preserved LVEF—a biochemical signature of subclinical myocardial stress.

Clinical profile of isolated DD versus normal phenotype (LVEF-preserved cohort, n = 80)

Isolated DD patients carried a substantially heavier cardiovascular comorbidity burden than Normal-phenotype patients (Table 1; Fig. 2A): diabetes 59.1% vs. 16.7% ($P < 0.001$), hypertension 77.3% vs. 50.0% ($P = 0.021$), prior cardiovascular history 72.7% vs. 44.4% ($P = 0.019$), NYHA ≥ 2 dyspnea 100% vs. 88.2% ($P = 0.051$, trend), elevated LVFP 22.7% vs. 0% ($P = 0.002$), and NT-proBNP > 300 pg/ml in 63.6% vs. 22.2% ($P = 0.001$).

Importantly, age, sex, obesity, dyslipidemia, and smoking did not differ between groups, and the median Lee score was identical (0 [0 to 0] vs. 0 [0 to 1], $P = 0.340$). Surgical risk class was also similar (high-risk surgery 22.7% vs. 16.7%, $P = 0.690$). This profile is consistent with isolated DD acting as a distinct pathophysiological signature rather than a mere proxy for a heavier conventional risk panel (Table 1).

Impact on preoperative management

UNDER PEER REVIEW IN IJAR

Detection of isolated DD significantly altered preoperative therapeutic decisions (Table 1; Fig. 2B): preoperative therapeutic adjustments occurred in 50.0% of Isolated DD patients versus 11.1% of Normal patients ($P < 0.001$; crude OR 8.00, 95% CI 3.00 to 21.00). Preoperative admission for optimization (40.9% vs. 22.2%, $P = 0.130$) and unplanned ICU admission (22.7% vs. 16.7%, $P = 0.690$) did not reach statistical significance. The 5-fold higher rate of therapeutic adjustment reflects clinicians' real-world risk perception—initiation or up-titration of beta-blockers, diuretics, statins, antithrombotics, and blood-pressure optimization—and may itself have attenuated downstream MACE differences (an outcome paradox we address in the Discussion).

Independent prognostic value of isolated DD for MACE

Sixteen of the 80 LVEF-preserved patients (20.0%) experienced perioperative MACE; rates were comparable between phenotypes (Normal 16.7%, Isolated DD 22.7%, $P = 0.690$) (Table 1). On univariable analysis, isolated DD was not a significant MACE predictor (OR 1.47, 95% CI 0.48 to 4.53; $P = 0.502$). Severe DD (isolated DD plus elevated LVFP) trended toward a stronger effect (OR 3.22, 95% CI 0.79 to 13.19; $P = 0.104$), although the analysis was power-limited (Table 2; Fig. 4).

The dominant univariable predictors of MACE were high-risk surgery (OR 16.11, 95% CI 4.32 to 60.05; $P < 0.001$), Lee score per point (OR 3.07, 95% CI 1.35 to 6.95; $P = 0.007$), and diabetes (OR 3.18, 95% CI 1.02 to 9.91; $P = 0.046$) (Table 2).

Combined-model performance and incremental value of DD

Predictive performance of competing models is shown in Table 4 and Fig. 3. Standalone discrimination of isolated DD for MACE was poor (AUC 0.55; sensitivity 62%, specificity 47%, positive predictive value [PPV] 23%, negative predictive value [NPV] 83%). The Lee score alone yielded an AUC of 0.66; the Lee + NT-proBNP base model reached 0.70.

Adding binary isolated DD to the Lee + NT-proBNP model produced no meaningful gain (AUC 0.70 → 0.70; ΔAUC = +0.002; bootstrap $P = 0.940$). In sharp contrast, adding severe DD (elevated LVFP) raised the AUC to 0.77—a +0.07 absolute improvement, consistent with a clinically relevant signal (Fig. 3B). The full multivariable model integrating Lee + NT-proBNP + isolated DD + surgical risk achieved an apparent AUC of 0.89 (bootstrap-corrected 0.85). High-risk surgery ($\beta = +3.585$; OR 36.06, 95% CI 5.83 to 222.97; $P < 0.001$) and Lee score ($\beta = +1.621$; OR 5.06, 95% CI 1.48 to 17.34; $P = 0.010$) retained significance; isolated DD alone did not ($\beta = -0.910$; OR 0.40, $P = 0.394$) (Table 3).

Diagnostic performance of isolated DD as a rule-out test

As a standalone diagnostic test for MACE, isolated DD had a sensitivity of 62%, a specificity of 47%, a PPV of 23%, and an NPV of 83% (Table 5). Although the PPV is too low to drive escalation, the 83% NPV gives the absence of DD a useful—if imperfect—rule-out role in routine preoperative practice.

Discussion:-

This prospective cohort study yields four findings that together motivate a reframing of preoperative diastolic assessment in non-cardiac surgery. First, isolated DD with preserved LVEF affects more than half of LVEF-preserved patients (55%)—a much higher prevalence than implied by current guideline texts [11,12]. Second, it carries a robust biochemical and clinical signature: a 7-fold higher median NT-proBNP and a marked excess of diabetes, hypertension, and prior cardiovascular disease, consistent with subclinical HFpEF [1,2]. Third, its independent prognostic contribution to in-hospital MACE is, in fact, modest: as a binary predictor, it adds no incremental discrimination over Lee + NT-proBNP. Fourth, and decisively, severity—captured by elevated LVFP—does carry a clinically meaningful prognostic signal, lifting model AUC from 0.70 to 0.77.

Our findings sit coherently within the most recent evidence base. The 2024 AHA/ACC/ACS perioperative guideline [11] explicitly notes that abnormal left ventricular systolic or diastolic function is associated with increased perioperative MACE, but that the incremental value of NT-proBNP beyond risk indices and self-reported functional capacity is small [18]. Our results extend this view: when DD is treated as binary, the incremental signal disappears almost completely, mirroring the discrimination ceiling reported for binary biomarker dichotomies. The Fayad et al. [14] systematic review and meta-analysis reported a pooled OR of approximately 1.7 for any DD and MACE—an effect that is real but small. Higashi et al. [27] showed that an $E/e' \geq 15$ (i.e., a severity criterion) tripled the risk of postoperative heart failure in intermediate-risk surgery, again consistent with severity—not presence—as the operative dimension.

UNDER PEER REVIEW IN IJAR

In the broader cardiology literature, DD severity has emerged as the dominant prognostic vector. The 2023 ESC focused update on heart failure [20] elevated sodium–glucose cotransporter-2 (SGLT2) inhibitors (dapagliflozin or empagliflozin) to a Class IA recommendation across the entire LVEF spectrum, including HFpEF, on the basis of the EMPEROR-Preserved and DELIVER trials [32,33]. Recent network meta-analyses confirm convergent benefit of SGLT2 inhibitors on cardiovascular death and heart-failure hospitalization in mildly reduced and preserved ejection fraction [28]. Although these therapies are not deployed perioperatively, they reframe the natural history we are trying to interrupt: preoperative isolated DD is not just an echocardiographic finding but a prognostic entry point into a treatable trajectory.

Recent imaging work also resonates with our central message. The SOLOMON study [19] showed that preoperative left ventricular global longitudinal strain modestly improved MACE prediction in non-cardiac surgery patients—consistent with our finding that more granular indices of myocardial function add value where binary classifications saturate. Meta-analyses of left atrial reservoir strain [29] support its prognostic role in HFpEF and across surgical cohorts, suggesting a future axis for refining the severity gradient.

On the basis of our data and the broader literature, we propose a pragmatic preoperative algorithm for non-cardiac surgery, which we term Severity-First Diastolic Triage (SFDT) (Fig. 5):

- Tier 1—Anchor on validated clinical predictors. Compute the Lee/RCRI score and identify high-risk surgery as defined by 2022 ESC criteria [12]. These two variables retain by far the strongest independent association with MACE in our and others' data.
- Tier 2—Reserve preoperative TTE for selected patients. Restrict routine preoperative echocardiography to patients with NT-proBNP > 300 pg/ml, unexplained dyspnea, or known/suspected heart failure—as already implied by the 2024 AHA/ACC [11] and 2022 ESC/ESAIC [12] guidelines, which discourage indiscriminate preoperative TTE.
- Tier 3—Stratify by DD severity, not its binary presence. When TTE is performed, classify diastolic function not only as present/absent but along the LVFP gradient. Isolated DD without elevated LVFP confers a small absolute MACE excess that does not justify systematic escalation; isolated DD with elevated LVFP markedly elevates risk and warrants preoperative cardiovascular optimization, anesthetic plan adaptation (cautious volume management, avoidance of tachycardia, appropriate intraoperative monitoring), and intensified postoperative surveillance.
- Tier 4—Use the absence of DD as a soft rule-out. The 83% negative predictive value of isolated DD alone (combined with Lee = 0 and NT-proBNP < 300 pg/ml) supports straightforward progression to surgery without further cardiac testing in the lowest-risk LVEF-preserved patients—aligning with the parsimony favored by the 2024 AHA/ACC update [11].

This framework moves the conversation from “is there DD?”—a binary that drives both over-triage and under-triage—to “how severe is the DD, and what does it mean alongside Lee and NT-proBNP?”. The full proposed algorithm is summarized in Fig. 5.

Our 5-fold higher rate of preoperative therapeutic adjustments in isolated-DD patients (50.0% vs. 11.1%) reveals an outcome paradox: clinicians already act on DD even when its independent prognostic value is small, and that pre-emptive action may itself attenuate the MACE difference observed at the bedside [30]. This is not an argument against assessment—it is an argument for targeted assessment, lest a finding that triggers expensive escalation in many patients dilute its own observable risk effect through pre-emptive correction. The SFDT framework formalizes this insight.

Pathophysiologically, the strong association of isolated DD with diabetes, hypertension, and elevated NT-proBNP places these patients on the HFpEF continuum [1,2,31]. The preoperative consultation thus becomes an unrecognized case-finding opportunity: identification of severe DD before surgery flags a population in whom postoperative initiation of guideline-directed HFpEF therapy (SGLT2 inhibitors per the 2023 ESC update [20]) may have benefits well beyond the immediate perioperative window—a hypothesis worth testing in interventional trials.

Strengths include the prospective design, consecutive enrollment, blinded echocardiographic assessment by a single experienced operator using current 2016 ASE/EACVI criteria, complete preoperative biomarker capture, and adjudicated outcomes. Reporting follows the STROBE and TRIPOD statements.

Several limitations deserve frank acknowledgment. First, the modest sample size (n = 80 in the primary comparison) and the limited number of MACE events (n = 16) leave the study underpowered to detect small-to-

UNDER PEER REVIEW IN IJAR

259 moderate independent effects of binary isolated DD. The non-significance of isolated DD as a MACE predictor
260 (P = 0.502) should be interpreted as absence of evidence, not evidence of absence. Second, single-center
261 recruitment limits external generalizability, particularly across surgical case-mix and ethnic backgrounds. Third,
262 the in-hospital composite endpoint mixes events of heterogeneous severity; longer-term outcomes (30-day, 90-
263 day, and 1-year MACE and mortality) were not captured. Fourth, although the operator was blinded, single-
264 reader echocardiographic interpretation introduces residual variability; multi-reader designs incorporating global
265 longitudinal strain and left atrial strain would strengthen future iterations. Fifth, high-sensitivity cardiac
266 troponin—now Class I in the 2022 ESC/ESAIC and 2024 AHA/ACC guidelines [11,12]—was not
267 systematically measured; its joint use with NT-proBNP and LVFP merits prospective study.

268 The SFDT framework requires external validation. Four research priorities follow:

269 • A multicenter prospective validation cohort (≥ 500 patients) powered to confirm the incremental
270 prognostic value of LVFP—not binary DD—over Lee + NT-proBNP, with longer follow-up (30-day and
271 1-year MACE).
272 • Integration of advanced echocardiographic markers—global longitudinal strain and left atrial reservoir
273 strain [19,29]—as continuous severity indices, potentially replacing the categorical LVFP threshold.
274 • A randomized pragmatic trial of "targeted TTE plus protocolized optimization" versus standard care in
275 NT-proBNP-positive patients, with hard cardiovascular outcomes.
276 • Implementation studies of SFDT-guided preoperative pathways with health-economic outcomes (cost per
277 MACE prevented, cardiology consultation rate, surgical-cancellation rate).

278 **Conclusion:-**

279 More than half of LVEF-preserved patients undergoing elective non-cardiac surgery have isolated diastolic
280 dysfunction. As a binary echocardiographic finding, isolated DD adds little to the prognostic discrimination
281 already achieved by the Lee score and NT-proBNP. Its severity—operationalized as elevated left ventricular
282 filling pressures—does carry a clinically meaningful incremental signal. Preoperative diastolic assessment
283 should therefore move from a binary alarm to a graded triage that integrates the Lee score, NT-proBNP, and
284 LVFP. The Severity-First Diastolic Triage framework operationalizes this shift and offers a pragmatic,
285 guideline-aligned pathway to rationalize preoperative decision-making in non-cardiac surgery.

286 **Conflicts of interest:-**

287 No potential conflict of interest relevant to this article was reported.

288 **Funding:-**

289 This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-
290 profit sectors.

291 **Ethics approval and consent to participate:-**

292 The study protocol was approved by the institutional ethics committee (Comité d'Ethique pour la Recherche
293 Biomédicale, Université Mohammed V, Rabat; approval number 31/25) and complied with the Declaration of
294 Helsinki (revised 2013). Written informed consent was obtained from every participant prior to inclusion.

295 **Data availability:-**

296 The anonymized individual participant data and the analytic code that support the findings of this study are
297 available from the corresponding author upon reasonable request, subject to approval by the local Institutional
298 Review Board.

299 **References:-**

300 1. Borlaug BA. Evaluation and management of heart failure with preserved ejection fraction. Nat Rev Cardiol 2020; 17: 559-
301 73.
302 2. Pieske B, Tschope C, de Boer RA, Fraser AG, Anker SD, Donal E, et al. How to diagnose heart failure with preserved
303 ejection fraction: the HFA-PEFF diagnostic algorithm. Eur Heart J 2019; 40: 3297-317.
304 3. Nagueh SF. Left ventricular diastolic function: understanding pathophysiology, diagnosis, and prognosis with
305 echocardiography. JACC Cardiovasc Imaging 2020; 13: 228-44.

UNDER PEER REVIEW IN IJAR

4. Reddy YN, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation 2018; 138: 861-70.

5. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.

6. Kuznetsova T, Herbots L, Lopez B, Jin Y, Richart T, Thijs L, et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009; 2: 105-12.

7. Wenzel JP, Bei der Kellen R, Magnussen C, Bonin-Schnabel R, Westermann D, Kirchhof P, et al. Diastolic dysfunction in individuals with and without heart failure with preserved ejection fraction: results from the Hamburg City Health Study. Clin Res Cardiol 2022; 111: 416-27.

8. Pirracchio R, Cholley B, De Hert S, Solal AC, Mebazaa A. Diastolic heart failure in anaesthesia and critical care. Br J Anaesth 2007; 98: 707-21.

9. Sanders D, Dudley M, Groban L. Diastolic dysfunction, cardiovascular aging, and the anesthesiologist. Anesthesiol Clin 2009; 27: 497-517.

10. Cho DH, Park SM, Kim MN, Kim SA, Lim H, Shim WJ. Presence of preoperative diastolic dysfunction predicts postoperative pulmonary edema and cardiovascular complications in patients undergoing non-cardiac surgery. Echocardiography 2014; 31: 42-9.

11. Thompson A, Fleischmann KE, Smilowitz NR, de las Fuentes L, Mukherjee D, Aggarwal NR, et al. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM guideline for perioperative cardiovascular management for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2024; 150: e351-442.

12. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J 2022; 43: 3826-924.

13. Flu WJ, van Kuijk JP, Hoeks SE, Kuiper R, Schouten O, Goei D, et al. Prognostic implications of asymptomatic left ventricular dysfunction in patients undergoing vascular surgery. Anesthesiology 2010; 112: 1316-24.

14. Fayad A, Ansari MT, Yang H, Ruddy T, Wells GA. Perioperative diastolic dysfunction in patients undergoing noncardiac surgery is an independent risk factor for cardiovascular events: a systematic review and meta-analysis. Anesthesiology 2016; 125: 72-91.

15. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016; 29: 277-314.

16. Duceppe E, Patel A, Chan MTV, Berwanger O, Ackland G, Kavsak PA, et al. Preoperative N-terminal pro-B-type natriuretic peptide and cardiovascular events after noncardiac surgery: a cohort study. Ann Intern Med 2020; 172: 96-104.

17. Rodseth RN, Biccard BM, Le Manach Y, Sessler DI, Lurati Buse GA, Thabane L, et al. The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: a systematic review and individual patient data meta-analysis. J Am Coll Cardiol 2014; 63: 170-80.

18. Wijeysundera DN, Pearse RM, Shulman MA, Abbott TEF, Torres E, Ambosta A, et al. Assessment of functional capacity before major non-cardiac surgery: an international, prospective cohort study. Lancet 2018; 391: 2631-40.

19. Kim M, Moon I, Bae S, Choi YJ, Lee SR, Kim TH, et al. Prognostic value of preoperative left ventricular global longitudinal strain for predicting postoperative myocardial injury and mortality in patients undergoing major non-cardiac surgery. Int J Cardiol 2023; 378: 151-8.

20. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023; 44: 3627-39.

21. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-7.

22. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100: 1043-9.

23. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J 2019; 40: 237-69.

24. Kaw R, Hernandez AV, Pasupuleti V, Deshpande A, Nagarajan V, Bueno H, et al. Effect of diastolic dysfunction on postoperative outcomes after cardiovascular surgery: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2016; 152: 1142-53.

25. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.

26. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 2015; 350: g7594.

UNDER PEER REVIEW IN IJAR

27. Higashi M, Shigematsu K, Tominaga K, Murakami Y, Iwashita Y, Suzuki T, et al. Preoperative elevated E/e' (>= 15) with preserved ejection fraction is associated with the development of postoperative heart failure in intermediate-risk non-cardiac surgical patients. J Anesth 2020; 34: 250-6.

28. Vaduganathan M, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, Inzucchi SE, et al. Prevention of cardiovascular events in heart failure with mildly reduced or preserved ejection fraction: a network meta-analysis of randomised controlled trials. eClinicalMedicine 2025; 87: 103352.

29. Pastore MC, Degiovanni A, Grisafi L, Renda G, Sozzi FB, Lerose C, et al. Left atrial strain to predict postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Circ Cardiovasc Imaging 2024; 17: e015969.

30. Devereaux PJ, Sessler DI. Cardiac complications in patients undergoing major noncardiac surgery. N Engl J Med 2015; 373: 2258-69.

31. Andersen MJ, Borlaug BA. Heart failure with preserved ejection fraction: current understandings and challenges. Curr Cardiol Rep 2014; 16: 501.

32. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Bohm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451-61.

33. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022; 387: 1089-98.

34. Devereaux PJ, Biccard BM, Sigamani A, Xavier D, Chan MTV, Srinathan SK, et al. Association of postoperative high-sensitivity troponin levels with myocardial injury and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2017; 317: 1642-51.

35. Sazgary L, Puelacher C, Lurati Buse G, Glarner N, Lampart A, Bolliger D, et al. Incidence of major adverse cardiac events following non-cardiac surgery. Eur Heart J Acute Cardiovasc Care 2021; 10: 550-8.

36. Borges FK, Furtado MV, Webber V, Polanczyk CA. Pre-operative high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide for cardiovascular risk stratification before major non-cardiac surgery. Eur J Anaesthesiol 2020; 37: 495-502.

37. Botto F, Alonso-Coello P, Chan MT, Villar JC, Xavier D, Srinathan S, et al. Myocardial injury after noncardiac surgery: a large, international, prospective cohort study. Anesthesiology 2014; 120: 564-78.

38. Park J, Kim J, Lee SH, Lee JH, Min JJ, Kwon JH, et al. Postoperative N-terminal pro-B-type natriuretic peptide and major adverse cardiac events after noncardiac surgery. Anesth Analg 2022; 134: 451-9.

39. Liem VGB, Hoeks SE, Mol KHJM, Potters JW, Grune F, Stolker RJ, et al. Postoperative hypotension and cardiovascular events: a meta-analysis. Br J Anaesth 2018; 121: 706-15.

40. Mol KHJM, Hoeks SE, Liem VGB, Stolker RJ, van Lier F. Postoperative troponin release is associated with major adverse cardiovascular events in the first year after noncardiac surgery. Int J Cardiol 2019; 280: 8-13.

41. Smilowitz NR, Beckman JA, Sherman SE, Berger JS. Hospital readmission after perioperative acute myocardial infarction associated with noncardiac surgery. Circulation 2018; 137: 2332-9.

42. Lurati Buse GA, Mauermann E, Ionescu D, Szczeklik W, De Hert S, Filipovic M, et al. Risk assessment for major adverse cardiovascular events after noncardiac surgery using self-reported functional capacity. Br J Anaesth 2023; 130: 655-65.

43. De Hert S, Staender S, Fritsch G, Hans J, Vandepitte WP, Beckers S, et al. Pre-operative evaluation of adults undergoing elective noncardiac surgery: updated guideline from the European Society of Anaesthesiology. Eur J Anaesthesiol 2018; 35: 407-65.

44. Park SJ, Choi JH, Cho SJ, Park JR, Lim SY, Kim SH, et al. Comparison of transthoracic echocardiography with N-terminal pro-brain natriuretic peptide as a tool for risk stratification of patients undergoing major noncardiac surgery. Korean Circ J 2011; 41: 505-11.

45. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010; 21: 128-38.

46. Esmati S, Tavoosi A, Mehrban S, Sharifian L, Falah G, Vatandoust E, et al. NT-proBNP level as a substitute for myocardial perfusion scan in preoperative cardiovascular risk assessment in noncardiac surgery. BMC Anesthesiol 2023; 23: 240.

47. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022; 400: 757-67.

UNDER PEER REVIEW IN IJAR

416 # Tables

417 **Table 1.** Clinical characteristics and perioperative outcomes by diastolic status (LVEF-preserved cohort, n =
418 80).

419

Variable	Normal (n = 36)	Isolated DD (n = 44)	P value
Age (yr), mean ± SD	67.6 ± 11.9	69.5 ± 9.4	0.900
Male sex, n (%)	10 (27.8)	16 (36.4)	0.570
Diabetes, n (%)	6 (16.7)	26 (59.1)	< 0.001
Hypertension, n (%)	18 (50.0)	34 (77.3)	0.021
Obesity, n (%)	8 (22.2)	14 (31.8)	0.480
Dyslipidemia, n (%)	8 (22.2)	8 (18.2)	0.870
Smoking, n (%)	4 (11.1)	8 (18.2)	0.530
Cardiovascular history, n (%)	16 (44.4)	32 (72.7)	0.019
Lee score, median (Q1, Q3)	0 (0, 0)	0 (0, 1)	0.340
Lee score ≥ 1, n (%)	8 (22.2)	14 (31.8)	0.480
NT-proBNP (pg/ml), median (Q1, Q3)	98 (59, 239)	733 (173, 981)	< 0.001
NT-proBNP > 300 pg/ml, n (%)	8 (22.2)	28 (63.6)	0.001
NYHA ≥ 2 dyspnea, n (%)	30/34 (88.2)	36/36 (100.0)	0.051
Elevated LVFP, n (%)	0 (0.0)	10 (22.7)	0.002
High-risk surgery, n (%)	6 (16.7)	10 (22.7)	0.690
Composite MACE, n (%)	6 (16.7)	10 (22.7)	0.690
Cardio-respiratory complications, n (%)	2 (5.6)	4 (9.1)	0.690
Postoperative ICU admission, n (%)	6 (16.7)	10 (22.7)	0.690
Therapeutic adjustment, n (%)	4 (11.1)	22 (50.0)	< 0.001
Preoperative admission, n (%)	8 (22.2)	18 (40.9)	0.130

420 *DD: diastolic dysfunction; ICU: intensive care unit; LVEF: left ventricular ejection fraction; LVFP: left ventricular filling pressures;*
421 *MACE: major adverse cardiovascular events; NYHA: New York Heart Association; Q1, Q3: first and third quartiles; SD: standard*
422 *deviation. Isolated DD was defined as preserved LVEF (≥ 50%) with abnormal diastolic function. Comparisons used the chi-squared or*
423 *Fisher's exact test for categorical variables and the Mann–Whitney U test for continuous variables.*

UNDER PEER REVIEW IN IJAR

424 **Table 2.** Univariable predictors of perioperative MACE (LVEF-preserved cohort, n = 80; 16 events).

425

Variable	OR (95% CI)	P value
Age (per 10 yr)	0.65 (0.38 to 1.11)	0.116
Diabetes	3.18 (1.02 to 9.91)	0.046
Hypertension	1.80 (0.52 to 6.22)	0.353
Obesity	1.80 (0.56 to 5.74)	0.320
Lee score (per point)	3.07 (1.35 to 6.95)	0.007
NT-proBNP > 300 pg/ml	2.44 (0.79 to 7.53)	0.122
High-risk surgery	16.11 (4.32 to 60.05)	< 0.001
Isolated DD (yes/no)	1.47 (0.48 to 4.53)	0.502
Severe DD (DD + elevated LVFP)	3.22 (0.79 to 13.19)	0.104
Elevated LVFP alone	3.22 (0.79 to 13.19)	0.104

426 *CI: confidence interval; DD: diastolic dysfunction; LVFP: left ventricular filling pressures; MACE: major adverse cardiovascular events;*
427 *OR: odds ratio. Univariable logistic regression. Isolated DD as a binary predictor is non-significant; severity (elevated LVFP) trends*
428 *toward a stronger association but is power-limited.*

429 **Table 3.** Multivariable logistic regression model of perioperative MACE.

430

Variable	β coefficient	OR (95% CI)	P value

Variable	β coefficient	OR (95% CI)	P value
Constant (intercept)	−3.521	—	< 0.001
Lee score (per point)	+1.621	5.06 (1.48 to 17.34)	0.010
NT-proBNP > 300 pg/ml	+1.274	3.58 (0.47 to 27.14)	0.218
Isolated DD (yes/no)	−0.910	0.40 (0.05 to 3.26)	0.394
High-risk surgery	+3.585	36.06 (5.83 to 222.97)	< 0.001

431 *CI: confidence interval; DD: diastolic dysfunction; MACE: major adverse cardiovascular events; OR: odds ratio. Apparent model AUC =*
432 *0.89; bootstrap-corrected AUC = 0.85 (1,000 replicates).*

433 **Table 4.** Discriminative performance of predictive models for perioperative MACE (area under the curve).

434

Model	AUC	ΔAUC vs. Lee + NT-proBNP
Lee score alone	0.66	—
NT-proBNP > 300 alone	0.61	—
Isolated DD alone	0.55	—
Elevated LVFP alone	0.58	—
Lee + NT-proBNP > 300	0.70	Reference
Lee + Isolated DD	0.67	—
Lee + NT-proBNP + Isolated DD	0.70	+0.002 (NS)
Lee + NT-proBNP + Severe DD (LVFP↑)	0.77	+0.07
Full model (Lee + NT-proBNP + DD + Surg.)	0.89 / corrected 0.85	—

435 *AUC: area under the receiver-operating-characteristic curve; DD: diastolic dysfunction; LVFP: left ventricular filling pressures; MACE:*
436 *major adverse cardiovascular events; NS: not significant. Binary DD does not improve the Lee + NT-proBNP base model; severity*
437 *(elevated LVFP) provides a clinically meaningful gain (+0.07).*

438 **Table 5.** Diagnostic performance of isolated DD as a standalone MACE predictor (LVEF-preserved cohort, n =
439 80).

440

Metric	Value (%)	Clinical interpretation
Sensitivity	62	62% of MACE occur in isolated-DD patients
Specificity	47	Low — many false positives
Positive predictive value (PPV)	23	23% of isolated-DD patients develop MACE
Negative predictive value (NPV)	83	83% of patients without isolated DD remain MACE-free

441 *DD: diastolic dysfunction; MACE: major adverse cardiovascular events; NPV: negative predictive value; PPV: positive predictive value.*
442 *The 83% NPV gives the absence of isolated DD a useful—if imperfect—rule-out role in routine preoperative practice, supporting the rule-*
443 *out tier of the Severity-First Diastolic Triage framework.*

444

UNDER PEER REVIEW IN IJAR

445 **Figure legends:-**

446 **Fig. 1. Echocardiographic phenotypes and NT-proBNP distribution.** (A) Phenotype distribution in the
447 cohort (n = 102): Normal 35.3%, Isolated DD 43.1%, SD + DD 19.6%, Isolated SD 2.0%. (B) NT-proBNP by
448 phenotype (log scale); the median was 7-fold higher in Isolated DD than in Normal (733 vs. 98 pg/ml, $P <$
449 0.001). The dashed line indicates the 300 pg/ml ESC/ESAIC threshold. DD: diastolic dysfunction; ESAIC:
450 European Society of Anaesthesiology and Intensive Care; ESC: European Society of Cardiology; SD: systolic
451 dysfunction.

452 **Fig. 2. Clinical profile and perioperative outcomes—Isolated DD versus Normal phenotype (n = 80).** (A)
453 Comorbidities significantly more frequent in Isolated DD: diabetes, hypertension, cardiovascular (CV) history,
454 NYHA ≥ 2, elevated LVFP, and NT-proBNP > 300 pg/ml. (B) Perioperative outcomes: the composite MACE
455 did not differ, but a 5-fold higher rate of therapeutic adjustment occurred in Isolated DD (50% vs. 11%, $P <$
456 0.001). *** $P < 0.001$; ** $P < 0.010$; * $P < 0.050$; † $P < 0.100$. DD: diastolic dysfunction; ICU: intensive care
457 unit; LVFP: left ventricular filling pressures; MACE: major adverse cardiovascular events; NYHA: New York
458 Heart Association.

459 **Fig. 3. Receiver-operating-characteristic curves for perioperative MACE prediction.** (A) Standalone
460 predictors: Lee score (AUC 0.66), NT-proBNP > 300 (AUC 0.61), isolated DD (AUC 0.55), elevated LVFP
461 (AUC 0.58). (B) Combined models: Lee alone (AUC 0.66), Lee + NT-proBNP (AUC 0.70), and Lee + NT-
462 proBNP + Severe DD (AUC 0.77). The shaded area represents the AUC gain (+0.07) from adding DD
463 severity—not binary DD—to the base model. AUC: area under the receiver-operating-characteristic curve; DD:
464 diastolic dysfunction; LVFP: left ventricular filling pressures; MACE: major adverse cardiovascular events.

465 **Fig. 4. Forest plot of univariable predictors of perioperative MACE (n = 80; 16 events).** Odds ratios with
466 95% confidence intervals from univariable logistic regression. Red bars indicate $P < 0.050$; gray bars indicate P
467 ≥ 0.050. High-risk surgery (OR 16.11), Lee score (OR 3.07 per point), and diabetes (OR 3.18) are significant.
468 Binary isolated DD (OR 1.47) is not, whereas severity (DD + elevated LVFP) trends stronger (OR 3.22). The
469 dashed vertical line indicates OR = 1. CI: confidence interval; DD: diastolic dysfunction; LVFP: left ventricular
470 filling pressures; MACE: major adverse cardiovascular events; OR: odds ratio.

471 **Fig. 5. Severity-First Diastolic Triage (SFDT) framework—proposed preoperative pathway.** A four-tier
472 algorithm: (1) anchor on the Lee/RCRI score and the ESC surgical risk classification; (2) reserve preoperative
473 transthoracic echocardiography (TTE) for NT-proBNP > 300 pg/ml, unexplained dyspnea, or known/suspected
474 heart failure (HF); (3) stratify diastolic findings by the LVFP gradient, not binary DD; and (4) use absence of
475 DD as a soft rule-out. The framework is aligned with the 2024 AHA/ACC, 2022 ESC/ESAIC, and 2023 ESC
476 HF focused-update guidelines. AHA/ACC: American Heart Association/American College of Cardiology; DD:
477 diastolic dysfunction; ESC/ESAIC: European Society of Cardiology/European Society of Anaesthesiology and
478 Intensive Care; HF: heart failure; LVFP: left ventricular filling pressures; RCRI: Revised Cardiac Risk Index;
479 TTE: transthoracic echocardiography.

480

UNDER PEER REVIEW IN IJA

Figures:-

Fig. 1.





Fig. 2.





Fig. 3.





Fig. 4.

489



490 **Fig. 5.**



491